A new study has brought scientists one step further in the direction of developing a cure for a brutal group of rare brain ...

An experimental gene therapy developed by researchers at UCLA, University College London and Great Ormond Street Hospital has ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

The stock makes the Nasdaq top gainers list today following news on the close yesterday. Genprex is trading at 0.7695, up ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative diseases in other parts of the body ...

Regeneron Pharmaceuticals, Inc. REGN announced updated data on its investigational gene therapy DB-OTO from the CHORD study.

An experimental gene therapy developed by researchers at UCLA, University College London and Great Ormond Street Hospital has ...

Researchers have achieved the first demonstration in mice of using gene therapy to reverse hallmark symptoms of ...

A patient has died in a clinical trial evaluating a Rocket Pharmaceuticals gene therapy shortly after complications emerged that led the FDA to pause the study. An inquiry into the fatality is ...

As newborn screening and rapid DNA sequencing become routine, we are poised to catch and treat inherited diseases at their earliest stages. Today, we can intervene in the first days or weeks of life.

Smarter design through targeted delivery and human-relevant testing can save the industry from costly safety failures.

LONDON, GREATER LONDON, UNITED KINGDOM, October 15, 2025 /EINPresswire.com/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And ...